ATNM vs DBVT vs IMVT vs NVO

For growth investors, Novo Nordisk A/S (NVO) is the stronger pick with 6.

4% revenue growth year-over-year, versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). Novo Nordisk A/S (NVO) offers the better valuation at 12. 6x trailing P/E (2. 1x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -83. 3% for Actinium Pharmaceuticals, Inc. (ATNM). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus ATNM's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DBV Technologies S.

A. (DBVT) is the lower-risk stock at 1. 26β versus Novo Nordisk A/S's 1. 56β — meaning NVO is approximately 24% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 67% for Novo Nordisk A/S — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novo Nordisk A/S (NVO) is pulling ahead at 6.

4% versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). On earnings-per-share growth, the picture is similar: Actinium Pharmaceuticals, Inc. grew EPS 30. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus -384. 4% for Actinium Pharmaceuticals, Inc. — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVO leads at 41. 3% versus -414. 9% for ATNM. At the gross margin level — before operating expenses — NVO leads at 81. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

In this comparison, NVO (4.

0% yield) pays a dividend. ATNM, DBVT, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Novo Nordisk A/S (NVO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (4.

0% yield). Both have compounded well over 10 years (NVO: +99. 6%, ATNM: -97. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ATNM is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; IMVT is a small-cap quality compounder stock; NVO is a large-cap deep-value stock. NVO pays a dividend while ATNM, DBVT, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.